Virginia lawmakers OK bills to expand access to CBD, THC-A oils
By Serena Fischer and Ben Burstein | Capital News Service
RICHMOND - In the final weeks of its 2019 session, the General Assembly passed three bills that would help people using cannabis-derived medications.
On Saturday, the House and Senate gave final approval to a bill allowing students who have proper documentation to use CBD oil and THC-A oil at school.
SB 1632, sponsored by Sen. Glen Sturtevant, R-Richmond, would prohibit schools from suspending or expelling a student for using CBD or THC-A oil with valid permission. The bill also would protect school nurses from prosecution of possessing and distributing the oils in accordance with school board policy.
Earlier in the month, legislators passed:
- SB 1557, introduced by Sen. Siobhan Dunnavant, R-Henrico. It would allow physician assistants and licensed nurse practitioners to write a certification for cannabidiol oil and THC-A oil.
- SB 1719, filed by Sen. David Marsden, D-Fairfax. It would allow patients receiving CBD or THC-A oil to designate a registered agent to pick up the medication on their behalf.
Dunnavant, the only physician in the Virginia Senate, has been an advocate for expanding access to medical cannabis.
“Allowing nurse practitioners to make treatment available will shorten the wait time and suffering for patients dealing with pain,” Dunnavant stated in support of SB 1557. “It is an effective way for physicians to offer low-cost and low risk remedies to their patients.”
Dunnavant hopes that expanding the use of cannabis-derived medications will help combat the growing opioid crisis.
“Overdose deaths related to prescribed opiates have decreased by 25 percent in states where medical marijuana programs are available. The potential side effects and risks of medically administered CBD and THC-A are far lower than opiates and many pharmaceutical drugs currently requiring a doctor’s prescription,” Dunnavant’s website states.
CBD, or cannabidiol, and THC-A, or tetrahydrocannabinolic acid, are two of the main compounds in the cannabis sativa plant.
Both components interact with cannabinoid receptors in the body that affect mood, pain, and memory. Neither contain the properties that produce a high. When raw, TCH-A has no psychoactive effects; only when burned does it become THC. Hemp, also a cannabis plant, is more widely used for CBD oil for its very low level of THC.
CBD and THC-A oils are used by many people to treat anxiety, migraines, nausea and other health problems. THC-A oils can achieve the same results as CBD oil but are less potent.
The U.S. Food and Drug Administration does not endorse any CBD or THC-A medication with the exception of Epidiolex, used to treat seizures from two rare forms of epilepsy. The U.S. Drug Enforcement Administration says it will support further research by the FDA into different components of cannabis.
“DEA will continue to support sound and scientific research that promotes legitimate therapeutic uses for FDA-approved constituent components of cannabis, consistent with federal law,” said Acting DEA Administrator Uttam Dhillon in a press release.
Virginia has moved slowly in allowing access to medical cannabis.
In 2015, the General Assembly passed legislation allowing CBD and THC-A oils only for the treatment of intractable epilepsy. Last year, lawmakers passed a bill sponsored by Dunnavant authorizing medical practitioners to recommend the oils to treat or ease the symptoms of any diagnosed disease or condition.
By expanding the definition of practitioner to include nurses, SB 1557 would make it even easier for Virginians to use the medical treatment.
“Expanding the availability of effective treatment options is both compassionate and practical,” Dunnavant said.
Capital News Service is a program of Virginia Commonwealth University’s Robertson School of Media and Culture. Students in the program provide state government coverage for a variety of media outlets in Virginia.